Literature DB >> 34120207

LI-RADS treatment response assessment of combination locoregional therapy for HCC.

Marielia Gerena1, Christopher Molvar2, Mark Masciocchi3, Sadhna Nandwana4, Carl Sabottke5, Bradley Spieler6, Rishi Sharma7, Leo Tsai8, Ania Kielar9.   

Abstract

HCC incidence continues to increase worldwide and is most frequently discovered at an advanced stage when limited curative options are available. Combination locoregional therapies have emerged to improve patient survival and quality of life or downstage patients to curative options. The increasing options for locoregional therapy combinations require an understanding of the expected post-treatment imaging appearance in order to assess treatment response. This review aims to describe the synergy between TACE combined with thermal ablation and TACE combined with SBRT. We will also illustrate expected imaging findings that determine treatment efficacy based on the mechanism of tissue injury using the LI-RADS Treatment Response Algorithm.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Arterial phase hyperenhancement; Combination locoregional therapy; Hepatocellular carcinoma; LI-RADS Treatment Response Assessment; SBRT; TACE; Thermal ablation

Mesh:

Substances:

Year:  2021        PMID: 34120207     DOI: 10.1007/s00261-021-03165-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  44 in total

1.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

2.  LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.

Authors:  Se Woo Kim; Ijin Joo; Hyo-Cheol Kim; Su Joa Ahn; Hyo-Jin Kang; Sun Kyung Jeon; Jeong Min Lee
Journal:  Eur Radiol       Date:  2020-01-31       Impact factor: 5.315

3.  The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.

Authors:  Mohammad Chaudhry; Katrina A McGinty; Benjamin Mervak; Reginald Lerebours; Cai Li; Erin Shropshire; James Ronald; Leah Commander; Johann Hertel; Sheng Luo; Mustafa R Bashir; Lauren M B Burke
Journal:  Radiology       Date:  2019-12-17       Impact factor: 11.105

4.  Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Authors:  Riccardo Lencioni; Robert Montal; Ferran Torres; Joong-Won Park; Thomas Decaens; Jean-Luc Raoul; Masatoshi Kudo; Charissa Chang; José Ríos; Valerie Boige; Eric Assenat; Yoon-Koo Kang; Ho-Yeong Lim; Ian Walters; Josep M Llovet
Journal:  J Hepatol       Date:  2017-01-26       Impact factor: 25.083

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.

Authors:  Katherine S Cools; Andrew M Moon; Lauren M B Burke; Katrina A McGinty; Paula D Strassle; David A Gerber
Journal:  Liver Transpl       Date:  2019-12-20       Impact factor: 5.799

7.  International trends in hepatocellular carcinoma incidence, 1978-2012.

Authors:  Jessica L Petrick; Andrea A Florio; Ariana Znaor; David Ruggieri; Mathieu Laversanne; Christian S Alvarez; Jacques Ferlay; Patricia C Valery; Freddie Bray; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2019-11-05       Impact factor: 7.316

Review 8.  mRECIST for HCC: Performance and novel refinements.

Authors:  Josep M Llovet; Riccardo Lencioni
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

9.  Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

Authors:  Bruno Vincenzi; Massimo Di Maio; Marianna Silletta; Loretta D'Onofrio; Chiara Spoto; Maria Carmela Piccirillo; Gennaro Daniele; Francesca Comito; Eliana Maci; Giuseppe Bronte; Antonio Russo; Daniele Santini; Francesco Perrone; Giuseppe Tonini
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

Review 10.  Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.

Authors:  Anum Aslam; Richard Kinh Gian Do; Avinash Kambadakone; Bradley Spieler; Frank H Miller; Ahmed M Gabr; Resmi A Charalel; Charles Y Kim; David C Madoff; Mishal Mendiratta-Lala
Journal:  World J Hepatol       Date:  2020-10-27
View more
  1 in total

Review 1.  Current Imaging Diagnosis of Hepatocellular Carcinoma.

Authors:  Evangelos Chartampilas; Vasileios Rafailidis; Vivian Georgopoulou; Georgios Kalarakis; Adam Hatzidakis; Panos Prassopoulos
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.